04 December, 2013. Link here. Leading veterinary biologic drug developer Nexvet Biopharma (Nexvet) today announced promising clinical data in support of its novel compound NV-01 for treating acute and chronic pain in dogs.
Chairman’s Address to 2013 Annual General Meeting here. AGM outcome of resolutions here.
ASX announcement here. Bioxyne Limited (ASX code: BXN or the Company) advises that subsequent to the execution of a non-binding Heads of Agreement (HOA) to sell its HI-164 oral Vaccine project together with all of its Intellectual properties (IP) to Mariposa Health Limited (MHL), Dr. Phillip Comans has stepped down as Chief executive Officer of the […]
Please find the ASX announcement here. Bioxyne divests its COPD related HI-164OV research program for up to $1.56 million.
..Two largest shareholders to vote against remuneration report 20 November 2013: Leading Australian life sciences investment group BioScience Managers today confirmed it will vote against the remuneration report of spray-on skin company Avita Medical Limited (ASX:AVH) at the company’s AGM on Friday 22 November. With the company’s largest shareholder Australian Ethical also set to vote against […]
Biota Initiates Additional Clinical Trials of Laninamivir Octanoate Link here. ATLANTA, Nov. 19, 2013 (GLOBE NEWSWIRE) — Biota Pharmaceuticals Inc. (“Biota”) (Nasdaq:BOTA) announced today that it has commenced dosing in two Phase 1 clinical trials of laninamivir octanoate (“LANI”), its long-acting neuraminidase inhibitor being developed for the treatment of influenza. One of the Phase 1 clinical trials is a […]
Financial report 2013 link here.
Link here. Date of Meeting: 22 November 2013 Time of Meeting: 2pm WST Place of meeting: Function Room, QV1, 250 St Georges Terrace, Perth, WA 6000
Link to the investor presentation here.